Six advocacy groups have asked the federal government to sidestep a handful of patents on a pricey drug used to treat a rare form of muscular dystrophy as part of an ongoing campaign to provide wider access to high-cost medicines.

In a letter sent on Wednesday to the Department of Health and Human Services, the groups argued that the patents — which are either owned or licensed by Sarepta Therapeutics (SRPT) — failed to disclose federal funding for grants that were used to develop a drug known as Exondys 51 for treating Duchenne muscular dystrophy. This is an accompanying memo sent to HHS.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • As a matter of healthcare ethics and public policy, the government should note that Sarepta, in its third quarter investor call, projected that they would generate $300M in revenues from Exondys 51 in 2018. The patient population or Exondys 51 is only 13% of the Duchenne population of only 2,000 – 3,000 people, or perhaps fewer than 300 people. Especially since Sarepta’s drug was developed from NIH funded research, this unconscionable pricing must be stopped.

  • President Trump, please make this very critical medicine affordable for anyone to purchase. Thank you.

  • In light of the pricing in this post, the fears reported earlier in the day of a tariff on Chinese raw materials causing rise in drug prices seem ….. overblown at a minimum and ludicrous as well.

Your daily dose of news in health and medicine

Privacy Policy